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Abstract
Since the guiding principles of Replace, Reduce, and Refine were published, wider
context-of-use for alternatives to animal testing have emerged. Induced pluripotent stem
cell-derived human glutamatergic-enriched cortical neurons can be leveraged as 2- and 3-
dimensional platforms to enable candidate drug screening. Uniquely so, 2-dimensional
models are useful considering that they exhibit spontaneous firing, while, 3-dimensional
models show spontaneous synchronized calcium transient oscillations. Here, the limita-
tions of selected induced acute seizure models as well as the early utilization of fully
differentiated glutamatergic neuron models for interrogation of inducible excitotoxicity
following exposure to neuromodulators will be described. The context of use for candi-
date biomarkers of inducible seizure is also discussed.
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1. Introduction
Animal models are often leveraged to evaluate neuronal function within an intact system [1];
yet, the “gold standard” of ex vivo evaluation of brain pathophysiology is “the brain slice
assay” [2]. Brain slice models lend to reduced numbers of animals for the conduct of neurosci-
ence research. While primary neuronal cell cultures derived from animals have supported
in vitro neuroscience studies for decades, their utility often leave to question possible transla-
tion to humans [3]. Human embryonic stem cell models were envisioned to provide more
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translatable context [4]. However, ethical bias towards stem cell procurement from embryos and
the lack of access to physiologically-relevant adult human brain tissues further encouraged
scientists to focus on the advancement of human induced pluripotent stem cell (iPSC)-derived
neuronal models [5]. Several iPSC-derived neurons have been developed to recapitulate net-
work behavior and signaling cascades on-a-dish reminiscent of phenotypes observed in
humans. Comprising the predominant excitatory network are glutamatergic neurons through-
out the cortex, cerebellum, hippocampus, striatum, thalamus, hypothalamus, and visual/audi-
tory system. Neuronal vesicles contain glutamate andmigrate to the synapse where they release
glutamate into the synaptic gap following Na+/K+ exchange (depolarization). More recently,
iPSC-derived human glutamatergic neurons were generated to support cell-based research
strategies [6]. Hence, researchers continue to learn and integrate these cutting-edge technologies
for early safety assessment. This chapter will spotlight the validation of glutamatergic neurons
as a platform for mechanistic assessment of inducible excitotoxicity in drug discovery.
2. Challenges when leveraging iPSC-derived human glutamatergic
neurons
Themost important tasks in using iPSC-derived human glutamatergic neurons is achieving large-
scale generation of human iPSC-derived neural stem cells/early neural progenitor cells in spite of
several challenges related to the differentiation procedures [7]. Terminal differentiation coupled
with preliminary cell model qualification steps often reveal how different iPSC lines made from a
single donor exhibit similar phenotypic marker expression as well as sensitivity to selected
neurotoxicants. Yet, a limitation of iPSCs, in general, is lot-to-lot variability, including optimiza-
tions of culturing conditions (e.g. medium, supplements), following advanced understanding of
how to optimal use such models to assess compound-related effects in vitro. The iCell®
GlutaNeurons (Cellular Dynamics International, a Fujifilm Company, cat. no. GNC-301-030-001)
were developed to provide a more physiologically relevant in vitro platform for de-risking
potentially translatable compound-induced neuronal toxicity early in the drug discovery process.
Notably, iCell® GlutaNeurons represent post-mitotic and highly pure populations (≥90%) of
human cortical glutamatergic neurons (Figure 1). According to the manufacturer, the iPS cell
lines were generated from human peripheral blood through ectopic expression of reprogramming
factors by episomal transfection. The iPS cell clones were engineered using nuclease-mediated
methodologies to exhibit neomycin resistance under the control of a neuronal-specific promoter.
When considering the impact of epigenetic factors state in neuronal development and differen-
tiation and that neurons derived from iPSCs offer a consistently reliable source of cells from a
single donor, baseline gene expression analysis profiles for novel iPSC-derived human
glutamatergic neurons represents another paramount validation step. Baseline single cell gene
transcription analyses was determined from iCell® GlutaNeurons at DIV7 and DIV21 using a
Biomark HD platform and custom assay reagents purchased from Fluidigm (Figure 2).
In general, a major challenge when leveraging hiPSC-derived GlutaNeurons is the lack of
endogenous mechanisms for detoxification as well as the ability to evaluate the impact of
different routes of administration (e.g., intramuscular and/or intraperitoneal injections) and
the inability to evaluate relevant co-morbidities which are observed in animal models and/or
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humans. Therefore, initial GlutaNeuron assessments rely on paradigm compounds that have
been previously well-characterized in vivo [8]. While they provide a way to model in vitro
glutamate excitotoxicity, iPSC-derived GlutaNeurons do not enable the determine relation-
ships between compound and brain segment-specific toxicological responses [9].
Figure 1. Human iCell® GlutaNeurons at DIV14. Fluorescence immunolabeling for phenotypic marker indicated neurons
(βIII-tubulin stain, green); non-neoplastic neurons (synaptophysin stain, red) and non-neuronal cells (40,6-diamidino-2-
phenylindole, DAPI stain, blue). Branched networks were observed rapidly (after 24 h) and remained viable and adherent
for an extended period in culture.
Figure 2. Targeted single-cell analysis to characterize gene transcription in untreated iCell® GlutaNeurons at DIV7 and
DIV21. We found that most cells were positive for glutamatergic gene transcripts in the absence of differential expression
at the two different time points. Abbreviations: GRIA—glutamate receptor, ionotropic, AMPA; GRIK—glutamate recep-
tor, ionotropic, kainate; GRIN—glutamate receptor, ionotropic, NMDA.
Induced Pluripotent Stem Cell-Derived Human Glutamatergic Neurons as a Platform for Mechanistic Assessment of…
http://dx.doi.org/10.5772/intechopen.77043
19
3. Glutamate excitotoxicity
There are three major classes of ionotropic glutamate receptors (iGluRs) and eight subtypes of
metabotropic glutamate receptors (mGluRs) [10]. The iGluRs are predominantly located in
postsynaptic sites and mediate rapid excitatory transmission, while mGluRs are expressed in
both neurons and glial cells and mediate delayed transmission. The amino acid L-glutamate
functions as an excitatory neurotransmitter that preferentially binds to iGluRs and mGluRs on
postsynaptic neurons which follows depolarization by Na+, K+, and Ca2+, resulting in an action
potential [11]. Conversely, the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)
functions to result in hyperpolarization of postsynaptic neurons [12]. Glutamate is synthesized
in neurons, while excessive glutamate is take up from the synaptic cleft by glial cells (astro-
cytes) via excitatory amino acids transporters EAAT1 and EAAT2 [13, 14]. In astrocytes,
glutamate is converted to glutamine by the enzyme glutamate synthase (GS). The glutamine
is transported back into presynaptic terminals via the “neuronal” excitatory amino acids
transporter EAAT3, where it is transformed by the glutaminase to yield glutamate that returns
to vesicles via vesicular glutamate transporters (vGLUT1 and vGLUT2). This biochemical
process is referred to as “the glutamate-glutamine cycle” [15]. Activation of mGluRs by gluta-
mate leads to intracellular inositol trisphosphate (IP3) turnover, activation of ryanodine recep-
tor channels in the endoplasmic reticulum (ER) membrane, and subsequent release of Ca2+
from the ER into the cytoplasmic space. Increased cytoplasmic Ca2+ can induce mitochondrial
uptake of Ca2+ which, if excessive, may result in the production of reactive oxygen species
(ROS) caused by prostaglandin/leukotriene formation and/or insufficient intracellular antioxi-
dants/free radical scavengers; production of reactive nitrogen species (RNS) and/or production
of apoptogenic factors; activation of calcium dependent phospholipases, endonucleases, and
proteases; untoward mitochondrial alterations (loss of buffering capacity); progressive neuro-
nal excitotoxicity; caspase activation; ATP depletion; and ultimately neuronal apoptosis,
necrosis and/or death [16–18]. Glutamate and structurally related analogs of glutamate can
interact with N-methyl D-aspartic acid receptors (NMDAR) under membrane depolarization
conditions (removal of intrinsic Mg2+ channel block of relative Ca2+-dependent responses),
resulting in large amounts of Ca2+ influx which activates downstream signal transduction
cascade to produce neurotoxic damage. These effects can be abrogated by antagonists. Addi-
tionally, binding of glutamate to a-amino-3-hydroxy-5-methy-4-isoxazole propionic acid
receptors (AMPAR) and/or kainate (KA) receptors (KAR) results in Na+ influx, membrane
depolarization and opening the voltage-dependent Ca2+ channels, signaling excitotoxicity.
Conversely, minimal excitotoxicity may follow mitochondrial depolarization, leading to
autophagy, a neuronal protective mechanism.
4. Kainate-induced rat status epilepticus model
In vitro platforms need to be coupled with in vivo models to establish translational relevance.
For example, kainate acid (kainate or KA)-induced rat status epilepticus model (Figure 3A) is
hallmarked by behavioral status epilepticus for up to 7 h following kainate injection coupled
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Figure 3. Hematoxylin and eosin staining and Fluoro-Jade B immunostaining in male Sprague Dawley rats that received
once daily intraperitoneal (I.P.) injections of either vehicle (saline for injection USP, n = 10) or kainate (8 mg/kg/day, n = 16)
for 7 consecutive days (A). In 9/16 KA-treated rats, mild to marked neuronal degeneration marked by increased Flouro-J
immunolabeling when compared to controls (B), ED1/CD68 immunolabeling, indicating increased microglial activation
(C) and GFAP immunolabeling, indicating increased astrogliosis (D) were identified in the hippocampus CA1-CA3
regions.
Table 1. Summary of brain histopathology finding in male Sprague Dawley rats that received once daily intraperitoneal
injections of kainate (8 mg/kg/day, n = 16) for 7 consecutive days. Brain tissues were unremarkable from the control group
rats that received vehicle (saline for injection USP, n = 10) for 7 consecutive days (data not shown).
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with brain lesions characterized by mild to marked neuronal degeneration (Table 1, Figure 3B),
microglial activation [increase in number] (Figure 3C) and astrogliosis (Figure 3D) in the
hippocampus CA1–CA3 regions.
5. Kainate-induced neuronal toxicity in-a-dish
Kainate-induced experimental seizure in animals replicate features of human temporal lobe
epilepsy (TLE), while neuronal toxicity in-a-dish models [19, 20] are useful because direct
exposure of cells to specific concentrations of compound results in the establishment of EC50
or IC50 concentrations. These cell-based models are usually dispersed in a monolayer bed,
with or without an astrocytic layer beneath it. Generally, 18-day-old fetal neurons are com-
monly used, and even “mature” for several weeks in culture, these neurons are not comparable
to adult neurons in vivo [21]. The excitatory iCell® GlutaNeurons were derived using iPSC
technology. Spontaneous electrical activity, including mean firing rat, was measured via micro-
electrode array (MEA) technology before and after reference compound application.
The human iCell® GlutaNeurons are differentiated from a master bank of stably iPSCs and
provided as cryopreserved single-cell suspensions in 1.5 ml frozen cryovials (containing at
least 5–6 million cells/vial) on dry ice. Upon receipt, the original vials were immediately
transferred to liquid nitrogen tank storage until defrosted for cell culture according to the
User’s Guide provided by the vender. At the time of plating, the cells were thawed for exactly
2 min in a 37C water bath. Complete BrainPhys medium comprised of the BrainPhys Neuro-
nal Medium, iCell DopaNeurons Medium Supplement, iCell Nervous System Supplement, N-
2 supplement, laminin, and penicillin-streptomycin. The Complete BrainPhys medium is
serum free and has been specially formulated whereby it enables cell viability and function
while limiting the proliferation of progenitor or non-neuronal cells. Cells were gently trans-
ferred to a 50 ml tube and 1 ml of the complete BrainPhys medium was added drop-wise and
swirled gently to minimize osmotic shock while an additional 8 ml of BrainPhys medium was
slowly added. The cell suspension was centrifuged at 400 g at room temperature for 5 min,
carefully aspirate the supernatant, and resuspend the cell pellet in 2-3 ml of the complete
BrainPhys medium after cell counting. The re-suspendered cells (100 μl/well) were seeded at
a density of 4  104 cells/well (12.5  104 cell/cm2) in a Corning 96-well white clear flat bottom
polystyrene microplate (Corning, New York), or at a density of 8  104 cells/well in an Axion
48-well MEA plate (Figure 4).
Cells were maintained at 37C (5% CO2) in the complete BrainPhys medium as describe below.
The cell culture plate well surfaces were freshly prepared with a base layer of Poly-L-ornithine
solution (0.01%; Sigma Aldrich) and a top coating of Matrigel solution (0.028 mg/ml; Sigma-
Aldrich), which are used to promote cell attachment, viability, and function. Spontaneous
electrical activity was recorded as described previously [23]. In general, homogeneous neuro-
nal populations produce spontaneous action potentials; therefore, mean firing rate (MFR)
reflects the action potentials over time which can be used in part to quantify cell functionality.
Multiple action potentials within a short time period represent neuronal burst. The cells were
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maintained at 37C in an incubator with 5% CO2 for several days in vitro (DIV) with exchange
of 50% of the medium every 2 days before treatment and subsequent parameter measure-
ments. Per our use, the iCell® GlutaNeurons were maintained in culture for up to 21 days in
culture medium without appreciable loss of viability (data not shown).
We tested glutamate receptor agonists and antagonists iCell® GlutaNeurons at DIV9, using
biochemical/functional assays to assess changes in cell viability, biomarker expression levels
and synaptic activity to systematically evaluate concentration and time dependent glutamate
excitotoxicity. Cells were treated with either vehicle (media or 0.1% DMSO), agonist (gluta-
mate), kainate (positive control agonist) or antagonist (NMDA-R Antagonist, MK801; KA-
R/AMPA-R Antagonist, NBQX; and FAAH Inhibitor, URB597) for up to 24 h, or pre-treated
with glutamate receptor antagonists or FAAH inhibitor for 1 h followed by an agonist for up to
24 h. Changes in cell density were determined subjectively using routine bright field micro-
scopic analysis (Figure 5). Concentration-dependent glutamate and kainate induced reductions
Figure 4. For example, the Axion classic 48-well MEA plates consist of wells with an array of 16 individually embedded,
nanotextured gold microelectrodes with four integrated ground electrodes, yielding a total of 768 channels across the
entire plate [22]. The culture plate temperature can be maintained at 37C using an integrated heating system and
temperature controller based on the low throughput maestro platform (Axion BioSystems, Inc.). The newer low through-
put, maestro PRO and high throughput, Maestro APEX platforms from Axion BioSystems Inc. (not shown) may also be
leveraged.
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in mean cell viability were assessed and compared at 30 min (acute effect; data not shown) and
24 h (lasting effect; Figure 6). For replicate wells for the same treatments, the mean values
relative to concurrent controls were used to calculate the area under the concentration curve
(AUC) in GraphPad Prism 7.0 software. After test compound treatment using the CellTiter-
Glo® Luminescent Cell Viability Assay kit (Promega Corporation, Madison,). Briefly, the
CellTiter-Glo® reagent added directly to cells culture medium results in cell lysis and genera-
tion of a luminescent signal (by luciferase reaction) proportional to the amount of ATP, which
is directly proportional to the number of viable cells present in culture. In this study, ATP levels
released from viable cells mitochondrial were measured in the 96-well plate format with
Figure 5. Changes in cell density of iCell® GlutaNeurons. Reductions in cell density were observed in GlutaNeuron-
astrocyte co-cultures following exposure to kainate (B) when compared to vehicle (A). Phenotypic changes were apparent
with glutamate only (C). Alone, no MK801- (D) or URB597- (E) related effects were observed. iCell® GlutaNeurons were
imaged in brightfield using an EVOS XL digital inverted microscope.
Figure 6. Mean cell viability of iCell® GlutaNeurons following exposure to glutamate (A, 63% loss) and kainate (B, 22%
loss) for 24 h when compared to controls. MK801 (NMDA antagonist, 10 μM = IC50) partially blocked the glutamate-
induced loss (~20%) of mean cell viability (C). FAAH inhibitor URB597, 50 mM) did not reduce the glutamate-induced
effects (D).
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approximately 4  104 or 8  104 cells/well 24 h after drug treatment using a microplate
luminescence reader. All experiments were performed in triplicate wells for each condition
(vehicle or per test compound concentration) and repeated at least three times. Blockade of KA-
induced effects on mean cell viability by pre-treatment with different concentrations of NBQX
was evident (data not shown).
The Axion BioSystems Maestro MEA technology is a label-free platform that measures electri-
cal activity of iCell® GlutaNeurons when cultured directly on MEA plates. Established algo-
rithms within Axion Integrated Studios (AxIS) v1.9 software can detect and quantify several
parameters to assess changes in neuronal functionality, excitability and connectivity. On DIV10
and DIV16, spontaneous network activity was recorded using Axion Biosystems Maestro 768
channel amplifier and AxIS) v1.9 software. The amplifier recorded from all channels simulta-
neously using a gain of 1200 and a sampling rate of 12.5 kHz/channel. After passing the
signal through a Butterworth band-pass filter (300–5000 Hz) on-line spike detection (thresh-
old = 8 rms noise on each channel) was done with the AxIS adaptive spike detector. All
recordings were conducted at 37C. Spontaneous network activity was recorded in the absence
of compounds for 4 min (baseline), then compounds were added and a continuous 30 min
(acute effects), or various time points (4 min/time points) up to 24 h (sub-chronic effects) of
activity were recorded. Only wells with 10 or more active electrodes (>5 spikes/min) during the
Figure 7. Kainate (A) and glutamate (B) induced changes in MFR in GlutaNeurons. MEA data showed that MK801
(10 μM) attenuated the glutamate (5 μM)-induced excitation at 4 and 24 h (C). Cells pre-exposed to URB597 reduced
glutamate (5 μM)-induced excitation at 4 and 24 h in GlutaNeurons (D).
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baseline recording period were used in the analysis. Stock solutions of compounds were made
to 100 the desired final concentration in 100 μl media, then 2 μl of stock solution was added
to each well (200 μl media) to reach the final desired concentration. Dedicated wells were used
on each 48 well plate for vehicle controls. At least three replicates of the viability assay and
were performed. At least triplicated wells were measured in each replicate. Following addition
of neat compounds, electric activity was recorded continuously for 30 min to determine the
acute effect on neuronal activity, or at different time points up to 24 h to determine the sub-
chronic effect on neuronal activity. Briefly, neurons synaptic activities (spontaneous or induced
action potentials) recorded in 4 min intervals at 2, 0 (baseline), 0.5, 2, 4 and 24 h post-
treatment, and MFR was used a biomarker to quantify functional changes in GlutaNeurons.
Between 0.5-24 h post treatment, pharmacologically relevant concentrations of kainate
(Figure 7A) and Glutamate (Figure 7B) induced changes in MFR in GlutaNeurons. MEA data
showed that MK801 (10 μM) attenuated the Glutamate (5 μM)-induced excitation at 4 and 24 h
(Figure 7C). Cells pre-exposed to URB597 reduced Glutamate (5 μM)-induced excitation at 4
and 24 h in GlutaNeurons (Figure 7D).
6. iPSC-derived neuronal models to enable early de-risking of inducible
neurotoxicity
Drug development is extremely costly and challenging [24]; moreover, lack of confidence in
translatability often leads to failure during clinical trials. Neurotoxicity caused by candidate
Figure 8. StemoniX’s 2D human MicroBrain® model is comprised of human iPS cells-derived cortical neurons and
astrocytes that are amendable to glutamatergic/GABAergic modulation. This model shows typical identity and functional
markers, including MAP2: Neuronal marker; GFAP: Astrocyte marker; Synapsin I: Neuronal functional (synapse) marker;
Aquaporin4: Astrocyte functional marker and DAPI: Nuclear marker [29–30].
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Figure 9. Changes in cell density of StemoniX’s pre-plated, assay ready high throughput 2D human glutamatergic
MicroBrain® platform (DIV33) imaged in bright field using an EVOS XL digital inverted microscope (A). Quantitative
reductions in cell density were observed following 24-h exposure to kainate when compared to vehicle (1% DMSO) using
a CellTiter-Glo® Luminescent Cell Viability Assay kit (B). Calcein-AM (blue line) and Annexin V (red line) assays were
used to detect kainate-induced loss of cell viability and increased apoptosis, respectively (C).
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drugs can lead to temporary or permanent harm to the central or peripheral nervous system.
In case of glutamate excitotoxicity, excessive stimulation of the neurons occurs due to brain
injury. Therefore, a major goal of the pharmaceutical industry has been to reduce late stage
compound attrition due to neurotoxicity. Pharmaceutical companies, consortia (the Health
and Environmental Sciences Institute) and regulatory authorities continue to establish more
predicative models and biomarkers for early identification of neurotoxicity [25]. It is gener-
ally accepted, that iPSC-derived GlutaNeurons offer advantages over in vivo models: (1)
isolated cells for glutamatergic signal transduction assessment in a dish; (2) low- and/or
high-throughput screening at less cost and time than in vivo study conduct, although the
MEA data interpretations may take several weeks; and (3) mechanistic assessment of neuro-
toxicity in vitro [26, 27]. Considering that candidate drugs may exhibit deleterious excitotoxic
liabilities, iPSC derived GlutaNeurons support screening tools for early de-risking potentially
translatable neurotoxicity. iCell® GlutaNeurons provide a relevant, excitatory neuronal model
that enables researchers to study human neuronal network development and activity through
interrogation and manipulation of relevant pathological pathways, thereby providing a new
and valuable tool for drug discovery.
Figure 10. The StemoniX 3D Human MicroBrain® model contains a balanced population of cortical neurons and
astrocytes which display typical identity and functional markers, including MAP2: Neuronal marker; GFAP: Astrocyte
marker; Synapsin I: Neuronal functional (synapse) marker; Aquaporin4: Astrocyte functional marker and DAPI:
Nuclear marker [30].
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Previous studies revealed changes in brain organoid viability, proliferation, differentiation,
and migration [28]. Newer human neural models try to replicate the brain complexity incor-
porating key features of the organ, such as the presence of a functional population of astro-
cytes. The MicroBrain® 2D model from StemoniX, (Figure 8) consists of a physiological
relevant mixture of human iPS cells-derived cortical neurons and astrocytes [29]. Tests using
this system have the potential of better recapitulate the intricate interplay between different
neural cells and physiological response observed in vivo (Figure 9).
Recently, 3D human brain organoids have been used to assess spontaneous and synchronized
neuronal activity and glutamate excitotoxicity. One interesting model is that the MicroBrain 3D
Assay Ready Plates® (StemoniX), which consists of human cortical neurons and astrocytes
spheroids (Figure 10) in 384-well format [29], containing one spheroid per well. These neural
brain organoids are highly homogenous in size at approximately 500 μm and show pheno-
typic markers of mature cellular (e.g., synaptic proteins and glutamate transporters). Quantifi-
able synchronized spontaneous calcium oscillations may be detected from this 3D MicroBrain
platform using a kinetic, high-throughput Fluorometric Imaging Plate Reader (FLIPR®). High
speed confocal imaging confirmed homogenous calcium oscillations at the cellular level,
whereas MEA analysis demonstrated robust synchronous glutamatergic/GABAergic circuitry.
Moreover, synchronized calcium oscillations may be utilized as a biomarker for neuronal
network activity in 3D MicroBrains. Finally, the MicroBrain 3D platforms are offered as pre-
plated cells delivered at room temperature, speeding up the turnover of results, dispensing the
need for long-term culture in the lab before the assay.
7. Recent advances in the development and validation sensitive and
specific biomarkers for drug-induced neurotoxicity using iPSC-derived
neuronal models
As noted above, pharmaceutical companies, the Health and Environmental Sciences Institute
consortia and regulatory authorities have committed resources intended for developing and
validating sensitive and specific biomarkers for early detection of drug-induced neurotoxicity
[25]. Recent studies have shown synchronized calcium oscillations as a useful biomarker for
neuronal network activity in CDI’s 2D GlutaNeurons using the Hamamatsu FDSS7000EX/
μCELL (a camera-based kinetic plate reader) [31] (Figure 11) and Stemonix’s 3D MicroBrains
using FLIPR [30] when cultured in 384-well plates (Figure 12). Synchronous spontaneous
(MicroBrain 3D) or 4-AP-induced (GlutaNeurons) calcium flux are evident in these in vitro
platforms. Taken together, inducible calcium flux in these models appears as a value-added
parameter to enable early discovery compound screening. Additional studies will reveal the
variables between in vivo calcium changes in the brain and those noted using various neuronal
on-a-dish models as well as the translational values for calcium flux to MEA data, when
monitoring for changes in electrophysiological parameters related to neurotoxin exposures.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate post-transcriptional gene
expression in pathologic processes and can be found in plasma, serum and brain tissue, for
example, circulating miRNA concentrations were differentially expressed in epilepsy patients
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compared healthy controls [32]. Notably, significantly decreased expression level changes in
serum hsa-miR-15a-5p showed sensitivity/specificity for diagnosis of epilepsy. To determine
the utility of miRNAs in a rat model of acute experimental seizure, we evaluated miRNA
expression level changes in serum as well as flash frozen cerebrum (cortex) and hippocampus
from male Sprague Dawley rats that received the prototype compound, pentylenetetrazol,
PTZ by single I.P. injection (Figure 13). In this study, single injection of PTZ at 60 mg/kg, I.P.
was a subconvulsive dose, while single injection of PTZ at 80 mg/kg, I.P. induced decreased
activity, straub tail, whole body tremor, heavy breathing, decreased body temperature (cold to
touch), and seizures (irregular clonus of head and fore and hind limbs) by approximately
20 min post dosing. Serum glucose (a conventional seizure biomarker) was increased at the
time of acute convulsive activity. Using the Abcam Fireplex™ Multiplex Rodent Discovery
miRNA Toxicity Panel, significantly upregulated (35) or downregulated (26) miRNA expres-
sion level changes were detected from PTZ-treated rats with seizures versus controls without
seizures; cerebral cortex revealed that miRNAs were significantly upregulated (1) or
downregulated (5) in the PTZ-treated rats versus controls; and hippocampus revealed that
miRNAs were significantly upregulated (8) or downregulated (3) in the PTZ-treated rats
versus controls (data not shown). The miRNA profiles differed between cerebral cortex and
hippocampus. As have been report for epilepsy patients, PTZ-induced acute seizures in rats
were characterized by significantly decreased expression level changes in miR-15a-5p in cere-
bral cortex and serum (Figure 12). Taken together, circulating miR-15a-5p could be a
minimally-invasive biomarker to enable monitoring for epilepsy in human patients [32] and
PTZ-induced rat models of acute seizure. Additionally, retrospective analysis revealed 6 sig-
nificantly upregulated miRNAs (mmu-mir-664-3p, mmu-mir-137-3p, mmu-mir-466i-5p, mmu-
mir-204-5p, mmu-mir-221-3p, mmu-mir-29c-5p) and 3 significantly downregulated miRNAs
(mmu-mir 324 5p, mmu-mir-140-5p, mmu-mir-328-3p) in male SD rats with seizures following
once daily injections of the KA (8 mg/kg/day, i.p.) for 7 consecutive days versus control
(vehicle: saline-treated) rats without seizures (author’s unpublished data). These miRNAs
showed promise as tissue-based exploratory biomarkers in rats with brain injury following
KA-induced experimental seizures. Additionally, early data suggest that selected miRNAs
detected from paraffin-embedded brain tissue slices may also correlate with profiles in hippo-
campal lesions (author’s unpublished data).
Figure 11. Representative detection of 4-aminopyridine (4-AP)-induced synchronization of calcium oscillations in CDI’s
2D GlutaNeurons at DIV28 (post seeding). Interestingly, spontaneous basal synchronized calcium flux activities are not
evident in CDI’s 2D GlutaNeurons. N = 4 replicates. 5-point dose concentration response condition. Each well was
normalized to concurrent control.
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Figure 12. Representative heat map of spontaneous basal synchronized calcium flux activity in StemoniX’s 3D Human
MicroBrain® (A) and characterization of synchronous glutamatergic calcium flux (30 min) post glutamate, kainate or
control treatment (B). N = 6 replicates. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (when compared to concurrent
control).
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When compared to those derived from animal models and/or animal-derived cell systems,
miRNAs from iPSC-derived human neuronal models which may have greater potential for
translation to human serum-based biomarkers. Interestingly, profiling of secreted miRNAs as
novel biomarkers of neurodegeneration in CDI’s iPSC-derived human neurons following acute
(24 h) exposure to selected neurotoxicants has been reported [33]. Lessons learned from these
studies included leveraging human iPSC-derived neurons at well-characterized stages of decline
in morphology as indicated by high-content imaging analysis of neurite outgrowth parameters
and cell viability (ATP release assay on replicate plates). Hence, CDI’s human iPSC-derived
neurons were treated at 2 h post-plating with 0.1–100 μM of neurotoxicants (including but not
limited to bisindolylmaleimide I, colchicine, doxorubicin, paclitaxel and rotenone) or acetamin-
ophen (negative control). Acute miRNA expression level changes were determined from condi-
tioned cell culture medium, while adhered cells were analyzed using high-content imaging
analysis. The low compounds concentrations had no/minimal effect on cell viability but with a
significant decrease in neurite outgrowth, while the high compound concentrations induced
significant decreases in both endpoints. No effect on any endpoint was observed with acetamin-
ophen. Where relevant, neurotoxins that induced at least a 2-fold change in miRNA expression
were potentially related to a decrease in neurite outgrowth, with further clustering based on
association to cell viability, yielding: (1) no effect, (2) significantly decreased, or (3) independent
of effect; indicating a relationship of miRNAs to progressive stages of neurodegeneration. While
further investigations are warranted, the miRNAs profiles identified in cell culture medium of
treated CDI’s iPSC derived neurons may have greater translation to human serum-based bio-
markers than those derived from either rodent cell lines and/or animal models of neurodegener-
ative disease(s). The usefulness of monitoring changes in miRNA profiles from 3D iPSC-derived
neuronal models (e.g., Stemonix’s 3D MicroBrains) has not been reported.
8. Summary
In vitro models support risk assessment in drug discovery and development. While, the extrap-
olation of toxicity data from animal models to humans is imperfect due to differences in ana-
tomy and physiology, these traditional models are used because they represent whole-organism
Figure 13. Male Sprague Dawley rats received a single I.P. injection of either vehicle (saline for injection USP, n = 10) or
pentylenetetrazol (PTZ, 80 mg/kg, n = 10). In 10/10 PTZ-treated rats, decreased activity, straub tail, whole body tremor,
heavy breathing, decreased body temperature (cold to touch), and seizures (irregular clonus of head and fore and hind
limbs) were evident by approximately 20 min post dosing. Significant increases in serum glucose concentrations were
detected in the PTZ-treated rats when compared to controls (A). Using the Abcam Fireplex™Multiplex Rodent Discovery
miRNA Toxicity Panel, PTZ-induced acute seizures in rats were characterized by significantly decreased expression level
changes in miR-106b-5p in cerebral cortex (B) and serum (C). *p < 0.05; **p < 0.01; ***p < 0.001 (when compared to
concurrent control).
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biology that is not well replicated by in vitro methods. Increasing pressure to Replace, Reduce,
and Refine the use of animal models in toxicity testing has propelled the use of in vitro systems to
characterize the cellular and molecular mechanisms underlying biological changes associated
with neurotoxicant exposure. The availability of iPSC-derived human GlutaNeuron cell models
(Figure 14) provides relatively easy access to previously unattainable cell types from the human
CNS system, which not only offer a unique source of neuronal cell types for candidate drug
screening, but also provide new platforms to enable addressing the limitations of conventional
animal models and primary cell cultures commonly used for mechanistic assessment of poten-
tially translatable inducible excitotoxicity in drug discovery.
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